Brought to you by 
Merck, Nastech terminate obesity deal
03 Dec 2015
Executive Summary
Merck & Co has licensed exclusive worldwide rights to nasal drug delivery firm Nastech Pharmaceutical's peptide YY 3-36 nasal spray (PYY), its Phase I candidate to treat obesity.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Macromolecule
- Nasal
-
Drug Delivery
-
Biotechnology
- Large Molecule
Deal Status
- Terminated
Deal Type
-
Alliance
- Co-Promotion
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Merck, Nastech terminate obesity deal
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice